Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab Cohort 3 included 41 ...
Cardiac Substructure Radiation Dose and Risk of Late Cardiac Disease in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study Eligible participants had mCRPC that progressed ...
Immune checkpoints are regulators of the immune system. The interaction between PD-L1 (red molecule) on the surface of a cancer cell (red) and the immune checkpoint PD-1 (blue molecule) on a T-cell ...
Please provide your email address to receive an email when new articles are posted on . Final OS results showed the anti-PD-1 therapy significantly reduced risk for death across subgroups when added ...
OCALA, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda ...
Please provide your email address to receive an email when new articles are posted on . Results showed a DFS benefit with the addition of pembrolizumab to chemotherapy for patients with mismatch ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results